While oncologic pain affects millions of people worldwide, advances in science and medicine bring new hopes. On February 1, 2024, before World Cancer Day, the WHO and its cancer research agency, the IARC, released new global estimates: in 2022, there were 20 million new cases, 9.7 million deaths, and 53.5 million people survived up to five years after diagnosis — about 1 in 5 people develop cancer during their lifetime. The organization warns about the unequal impact of the disease, especially in underserved populations, and the lack of adequate funding for priority services and palliative care in many countries (WHO, 2024).

Faced with this scenario, among opioids, anti-inflammatories, and innovative therapies, medicinal cannabis emerges as a promising alternative, offering pain relief and a better quality of life for patients battling cancer.

Expanding Global Market

The oncologic pain market, valued at $6.53 billion in 2024, is set to nearly double by 2034, reaching $11.81 billion, with a Compound Annual Growth Rate (CAGR) of 6.10%. The increasing cancer prevalence, along with the growing geriatric population, drives the demand for effective treatments to relieve pain and enhance patients' quality of life.

Read Also:

From Pain to Relief: When Cannabis Becomes an Ally in Cancer Treatment

The Role of Cannabis in Cancer Treatment

Pharmaceutical Innovations and Alternative Therapies

Leading pharmaceutical companies, such as Eli Lilly, Pfizer, and Johnson & Johnson, are spearheading research and launching new medications, ranging from opioids and non-opioids to nerve blockers and targeted therapies. Recent studies indicate that medicinal cannabis can reduce opioid use by up to 32%, establishing itself as a promising alternative for pain management.

Regional Perspective and Opportunities

North America dominates the market, driven by advanced healthcare systems and a higher cancer prevalence. Europe, Japan, and India are also expected to show accelerated growth. Governments and institutions are intensifying awareness initiatives and research investments, creating room for new therapies and collaborative strategies among pharmaceutical companies.